Palvella Therapeutics Announces $10 Million in Funding from Ligand Pharmaceuticals to Accelerate PTX-022 through Phase 2/3 Clinical Study in Pachyonychia Congenita
– Fast Track-Designated Program Commencing Phase 2/3 Study in Q1 2019 –¬†

See more here


Relmada Therapeutics Presents Clinical Data on Increased BDNF Plasma Levels in Subjects Treated with REL-1017
Findings on Effect of REL-1017 on BDNF Plasma Levels Presented at Annual Meeting of the American College of Neuropsychopharmacology 

See more here


CEO of Group K Diagnostics Nominated to the Philadelphia Startup Leaders Board

See more here


Pillo Health Launches Innovative Home Health Assistant to Dispense Medication, Track Adherence, Deliver Care Plans

See more here


Palvella Therapeutics Announces FDA Fast Track Designation for PTX-022 for Treatment of Pachyonychia Congenita

See more here


Oncora Medical teams up with oncologists at N.Y.’s largest health system

See more here


Palvella Therapeutics to Present Update on PTX-022 at Pachyonychia Congenita Project Patient Support Meeting in London, UK

See more here